- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03652935
Mindfulness, Breast Cancer and Psycho-Immune Dysregulation
Mindfulness Based Stress Reduction for Psycho-Immune Dysregulation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Mindfulness-Based Stress Reduction (MBSR) program is designed to cultivate conscious awareness (i.e., mindfulness) of one's experience in a non-judgmental or accepting manner (Kabat-Zinn, et al., 1990). Mindfulness programs may facilitate recovery from cancer. However, most prior mindfulness investigations for women with breast cancer focused on cancer survivors, well beyond the acute period of cancer diagnosis and treatment. Moreover, few of these studies evaluated immune measures with relevance to cancer.
Women diagnosed with early stage breast cancer (Stages 0, 1, 2, and 3) will be enrolled. Eligible women will be identified after completion of their breast surgery and when surgical pathology reports are available. Women will complete psychometric instruments and study questionnaires. They will provide blood for immune measures and saliva for cortisol diurnal rhythm. Measures will be done at five separate time points. These are pre-, mid-, and completion of either the MBSR or the attention control program, as well as at 1- and 6-months post-program. Demographic information and information about health behaviors will be collected by self-report. Wrist actigraphy for an additional assessment of sleep quality will be done in an exploratory manner. Hierarchical linear modeling will be used to compute multilevel model for change, based on full maximum likelihood estimation (Raudenbush, S. W., and A. S. Bryk. 2002). Hierarchical linear modeling will be applied to examine intra-individual and inter-individual differences in initial status (baseline) and trajectories of change over time.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women
- Early Stage Breast Cancer
Exclusion Criteria:
- Prior training in MBSR,
- Recurrent breast cancer,
- Metastatic breast cancer,
- Other cancers (except basal cell carcinoma),
- Immune-based disease,
- Psychoses,
- Cognitive dysfunction,
- Unable to read or write English,
- History of substance abuse,
- Use of immune-altering medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mindfulness Based Stress Reduction
The Mindfulness Based Stress Reduction (MBSR) program consists of an 8-week (2.5 hr/wk) program with a 6-hour silent mindful practice retreat after the fifth week.
A licensed clinical psychologist, certified as an MBSR instructor, will provide instruction to all groups.
Mindfulness will be taught using breath awareness, sitting and walking meditation, and mindful yoga.
Participants will be given a standardized session-by-session program workbook containing weekly objectives and assignments, as well as two practice recordings and the book, Full Catastrophe Living (Kabat-Zinn, J, 1990).
|
|
Active Comparator: Health Education Series
The active comparator condition consists of an 8-week educational series, administered in group-format, and matched in duration and frequency to the MBSR program.
Session topics include: 1) Understanding Breast Cancer and Risks for Breast Cancer, 2) Breast Cancer Treatment, 3) Communicating Effectively with your Health Care Providers; Keeping your Medical Records, 4) Genetic Testing and Cancer, 5) Nutrition and Cancer, (6) Cooking Demonstration, 7) Bone Health, and 8) Image and Cancer (American Cancer Society - Look Good, Feel Better).
The program content and objectives were reviewed by four content experts (oncology clinicians) and two breast cancer survivors.
|
This is an active comparator condition that consists of 8 weekly classes related to health.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Natural Killer Cell Activity
Time Frame: Change from baseline NKCA to 36 weeks.
|
Natural killer cell lytic activity (NKCA) against tumor targets will be assessed ex vivo using participant peripheral blood mononuclear cells (PBMC) in a standard chromium release assay, as we described previously (Witek-Janusek, L. et al., 2007).
|
Change from baseline NKCA to 36 weeks.
|
Change in Cytokine Levels
Time Frame: Change from baseline cytokine level to 36 weeks.
|
Plasma levels of cytokines, Interleukin 6 (IL-6) and Tumor Necrosis Factor (TNF) alpha and PBMC cytokine production of these cytokines and interferon (IFN) gamma will be determined.
Measurement of individual cytokines will be by quantitative sandwich enzyme immunoassay (R & D Systems, Minneapolis, MN), as we described previously (Witek-Janusek, L. et al., 2007; Witek-Janusek, et al., 2008).
|
Change from baseline cytokine level to 36 weeks.
|
Change in Perceived Stress
Time Frame: Change from baseline perceived stress level to 36 weeks.
|
The construct, perceived stress, will be measured using the Perceived Stress Scale (Cohen, S. et al., 1983).
The Perceived Stress Scale is a 10-item instrument that assesses the degree to which life experiences are appraised as uncontrollable.
Individual items are summed, with scores ranging from 0 (minimum) to 40 (maximum); higher scores indicate higher perceived stress.
|
Change from baseline perceived stress level to 36 weeks.
|
Change in Depression
Time Frame: Change from baseline depression level to 36 weeks.
|
The construct, depression, will be measured using the Center for Epidemiologic Studies - Depression scale.
This is a 20-item measure that asks individuals to rate how often over the past week they experienced symptoms associated with depression.
Individual items are summed with scores ranging from 0 (minimum) to 60 (maximum); higher scores indicate greater depressive symptoms (Radloff, LS, 1977).
|
Change from baseline depression level to 36 weeks.
|
Change in Fatigue
Time Frame: Change from baseline fatigue level to 36 weeks.
|
The construct, fatigue, refers to a subjective sense of tiredness.
Fatigue will be measured using the Multidimensional Fatigue Symptom Inventory-Short Form, which consists of 30 items that assess the extent of fatigue experienced by the respondent.
Individual items are summed with scores ranging from -24 to 96.
Higher score indicates greater fatigue (Stein, KD, et al., 2004).
|
Change from baseline fatigue level to 36 weeks.
|
Change in Sleep
Time Frame: Change from baseline sleep quality level to 36 weeks.
|
The construct, sleep quality, will be measured using the Pittsburgh Sleep Quality Index, which consists of 19 items that measure a person's perception of their sleep quality.
An overall score is calculated by summing items.
Scores range from 0 (minimum) to 21 (maximum), where lower scores denote a better sleep quality (Buysse, DJ, et al., 1989).
|
Change from baseline sleep quality level to 36 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cortisol
Time Frame: Change from baseline cortisol level to 36 weeks.
|
Cortisol diurnal rhythm is determined by repeated measure of salivary cortisol (Kirschbaum, C and Hellhammer, DH. 1994).
This allows frequent non-invasive sampling under everyday conditions.
Subjects will collect saliva samples upon awakening (within 15 minutes of awakening), and at 1200, 1700, and 2200 hr on 2 consecutive days.
Centrifuged samples will be frozen and assayed in duplicate using immunoassay kits (Salimetrics™), which measure biologically active (non-protein bound) cortisol.
|
Change from baseline cortisol level to 36 weeks.
|
Change in Quality of Life in Cancer
Time Frame: Change from baseline quality of life level to 36 weeks.
|
The construct, quality of life, will be measured using the Quality of Life Index Cancer Version III.
Quality of life refers to "a person's sense of well-being that stems from satisfaction or dissatisfaction with the areas of life that are important to him/her."
Items are summed to provide global quality of life, with score ranging from 0 (minimum) to 30 (maximum); higher scores indicate better quality of life (Ferrans, CE, 1990).
|
Change from baseline quality of life level to 36 weeks.
|
Change in Social Support
Time Frame: Change from baseline social support level to 36 weeks.
|
The construct of social support refers to the extent to which a person's social relationships provide support.
Social support will be measured using the 24-item Social Provisions scale, which measures the degree of perceived social support.
Responses to items are summed and scores range from 24 to 96;a higher score indicates a greater degree of perceived support (Cutrona CE and Russell DW,1987).
|
Change from baseline social support level to 36 weeks.
|
Change in Coping
Time Frame: Change from baseline to 36 weeks.
|
The construct of coping with cancer will be measured using the Jalowiec Coping Scale.
The Jalowiec Coping Scale is a 60 item self-report measure assessing efficacy of coping behaviors.
The JCS allows for the respondent to identify which coping behaviors he/she uses and to then rate the effectiveness of that coping behavior.
A score of coping effectiveness is calculated.
Scores can theoretically range between 0 and 180, with higher scores indicating greater use of coping behaviors (Jalowiec A, et al., 1984).
|
Change from baseline to 36 weeks.
|
Change in Wrist Actigraphy Measure of Sleep Quality
Time Frame: Change from baseline actigraphy to 36 weeks.
|
Wrist Actigraphy will be used as a measure of sleep quality (Morgenthaler, T. et al. 2007).
Women will be given an Actiwatch (Respironics) and asked to wear the Actiwatch for 6 days (non-dominate wrist).
Actiwatch software will be used to calculate a composite of sleep quality.
|
Change from baseline actigraphy to 36 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Linda Janusek, PhD, Loyola University Chicago
Publications and helpful links
General Publications
- Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available.
- Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
- Morgenthaler T, Alessi C, Friedman L, Owens J, Kapur V, Boehlecke B, Brown T, Chesson A Jr, Coleman J, Lee-Chiong T, Pancer J, Swick TJ; Standards of Practice Committee; American Academy of Sleep Medicine. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep. 2007 Apr;30(4):519-29. doi: 10.1093/sleep/30.4.519.
- Kirschbaum C, Hellhammer DH. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology. 1994;19(4):313-33. doi: 10.1016/0306-4530(94)90013-2.
- Cutrona CE and Russell DW. 1987. The provisions of social relationships and adaptation to stress. Advances in Personal Relationships. 1:37-6.
- Ferrans CE. Development of a quality of life index for patients with cancer. Oncol Nurs Forum. 1990 May-Jun;17(3 Suppl):15-9; discussion 20-1.
- Jalowiec A, Murphy SP, Powers MJ. Psychometric assessment of the Jalowiec Coping Scale. Nurs Res. 1984 May-Jun;33(3):157-61.
- Kabat-Zinn, J. 1990. Full Catastrophe Living. Delacorte, New York.
- Radloff, LS 1977. The CES-D Scale: A self-report depression scale for research in the general population. Applied Psychological Measurement 1:385-401. doi.org/10.1177/014662167700100306
- Raudenbush, SW and Bryk, AS. 2002. Hierarchical Linear Models: Applications and Data Analysis Methods, 2 ed. Sage, Thousand Oaks, CA.
- Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage. 2004 Jan;27(1):14-23. doi: 10.1016/j.jpainsymman.2003.06.003.
- Witek-Janusek L, Gabram S, Mathews HL. Psychologic stress, reduced NK cell activity, and cytokine dysregulation in women experiencing diagnostic breast biopsy. Psychoneuroendocrinology. 2007 Jan;32(1):22-35. doi: 10.1016/j.psyneuen.2006.09.011. Epub 2006 Nov 7.
- Witek-Janusek L, Albuquerque K, Chroniak KR, Chroniak C, Durazo-Arvizu R, Mathews HL. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. Brain Behav Immun. 2008 Aug;22(6):969-81. doi: 10.1016/j.bbi.2008.01.012. Epub 2008 Mar 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Mindfulness Based Stress Reduction
-
Duke UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Inflammation | Stress, Psychological | SleepUnited States
-
University of California, San FranciscoCompletedDementia | Frontotemporal Dementia | Frontotemporal Lobar Degeneration | Caregiver Stress Syndrome | Caregiver Burnout | Dementia Frontal | Mindfulness Based Stress ReductionUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruiting
-
Oregon Health and Science UniversityPortland VA Medical CenterCompleted
-
Chang Gung Memorial HospitalRecruitingLate Life DepressionTaiwan
-
Schneider Children's Medical Center, IsraelCompletedInflammatory Bowel DiseasesIsrael
-
Clemson UniversityUniversity of California, Los Angeles; Prisma Health-UpstateCompletedQuality of Life | Diabetes | Stress | Health Behavior | Pre-DiabetesUnited States
-
University of AarhusVU University of AmsterdamUnknown
-
Johns Hopkins UniversityCompleted
-
Spaulding Rehabilitation HospitalCompletedStress | Brain Injury | Traumatic Brain InjuryUnited States